|
|
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial
/
Iveson, Timothy J (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ;
Kerr, Rachel S (Department of Oncology, University of Oxford, Oxford, UK) ;
Saunders, Mark P (The Christie Hospital, Manchester, UK) ;
Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Hollander, Niels Henrik (Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark) ;
Tabernero, Josep (VHIO) ;
Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ;
Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ;
Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ;
Boyd, Kathleen Anne (Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK) ;
Briggs, Andrew (Center for Health and Policy Outcomes, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre, Glasgow UK) ;
Medley, Louise (Royal United Hospital, Bath, UK) ;
Wilson, Charles (Addenbrookes Hospital, Cambridge, UK) ;
Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ;
Dhadda, Amandeep S (Castle Hill Hospital, Hull, UK) ;
Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ;
Olesen, Rene K (Department of Oncology, Aarhus University Hospital, Aarhus, Denmark) ;
Propper, David (Barts Cancer Institute, Queen Mary University of London, London, UK) ;
Bridgewater, John (UCL Cancer Institute, University College London, London UK) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust, Brighton, UK) ;
Cunningham, David (Royal Marsden Hospital, London, UK) ;
Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ;
Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S (Hammersmith Hospital, Imperial College London, London, UK) ;
Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 -  10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
